About Choroidal Neovascularization
Choroidal neovascularization is the formation of new blood vessels in the choroid layer of the eye. These vessels grow through the Bruch membrane into the subretinal space, blocking the proper functioning of retina and leading to vision loss. The condition is often associated with myopia, malignant myopic degeneration, or age-related macular degeneration (AMD).
Technavios analysts forecast the global choroidal neovascularization market to grow at a CAGR of 6.64% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global choroidal neovascularization market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of choroidal neovascularization.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavios report, Global Choroidal Neovascularization Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Bayer HealthCare
Novartis
Regeneron Pharmaceuticals
F. Hoffmann-La Roche
Other prominent vendors
Alcon
Allergan
Avalanche
Bausch and Lomb
Gilead Sciences
Iconic Therapeutics
Lpath
Neurotech Pharmaceuticals
Ohr Pharmaceutical
Opthea
Ophthotech
PanOptica
Pfizer
Promedior
QLT
Quark
Resolvyx Pharmaceuticals
RXi Pharmaceuticals
Sagent Pharmaceuticals
Santen
Sanwa Kagaku Kenkyusho
Market driver
Growing older population
For a full, detailed list, view our report
Market challenge
High cost of treatment
For a full, detailed list, view our report
Market trend
Strategic alliances and M&A
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Disease overview
Introduction
Pathophysiology
Symptoms
Management
Epidemiology
PART 06: Product portfolio of approved therapies
PART 07: Pipeline analysis
OHR-102
RTH258
Fovista
RG7716
PF-04523655
NT-503
LFG316
REGN2176-3
Zimura
LHA510
DE-120
PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 09: Market segmentation by ROA
IV
Intravitreal
PART 10: Geographical segmentation
Global choroidal neovascularization market by geographical segmentation 2015-2020
Choroidal neovascularization market in Americas
Choroidal neovascularization market in EMEA
Choroidal neovascularization market in APAC
PART 11: Market drivers
Growing older population
Increased prevalence of chronic diseases
High patient and physician satisfaction
Increase in diagnosis rate
PART 12: Impact of drivers
PART 13: Market challenges
High cost of treatment
Limited public awareness
Side effects associated with treatment options
Availability of alternative therapies
PART 14: Impact of drivers and challenges
PART 15: Market trends
Strategic alliances and M&A
Increased initiatives and programs
Use of combination therapies
Increase in R&D
PART 16: Vendor landscape
Competitive scenario
Market analysis 2015
F. Hoffmann-La Roche
Novartis
Regeneron Pharmaceuticals
Bayer HealthCare
Other prominent vendors
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings 7
Exhibit 02: Key buying criteria for choroidal neovascularization drugs
Exhibit 03: Types of choroidal neovascularization
Exhibit 04: Symptoms of choroidal neovascularization
Exhibit 05: Treatment options for choroidal neovascularization
Exhibit 06: Pipeline portfolio: Global choroidal neovascularization therapeutics
Exhibit 07: Global choroidal neovascularization market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global choroidal neovascularization market by ROA 2015
Exhibit 10: Market segmentation by geography 2015
Exhibit 11: Choroid neovascularization market revenue by geography 2015-2020 ($ billions)
Exhibit 12: Choroidal neovascularization market in Americas 2015-2020 ($ billions)
Exhibit 13: Choroidal neovascularization market in EMEA 2015-2020 ($ billions)
Exhibit 14: Choroidal neovascularization market in APAC 2015-2020 ($ millions)
Exhibit 15: Global choroidal neovascularization market: YoY growth and revenue based on geography 2015-2020
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Vendor ranking of global choroidal neovascularization market 2015
Exhibit 19: Roche: YoY growth and revenue of Avastin 2011-2014 ($ billions)
Exhibit 20: Roche: YoY growth and revenue of Lucentis 2011-2014 ($ billions)
Exhibit 21: Roche: Key takeaways
Exhibit 22: Novartis' specialty ophthalmic segmentation by revenue 2014
Exhibit 23: Novartis: YoY revenue and growth rate of Lucentis (excluding the US) 2012-2014 ($ millions)
Exhibit 24: Novartis: Key takeaways
Exhibit 25: Regeneron: YoY revenue and growth rate of EYLEA (in the US) 2012-2014 ($ billions)
Exhibit 26: Regeneron Pharmaceuticals: Key takeaways
Exhibit 27: Bayer HealthCare: YoY revenue and growth rate of EYLEA 2012-2014 ($ millions)
Exhibit 28: Bayer HealthCare: Key takeaways
